Core Viewpoint - The Hong Kong stock market's 18A biotech sector is experiencing a resurgence in IPOs, with a significant shift in investor sentiment towards a more cautious evaluation of companies based on commercial maturity, cash flow sustainability, and clear value propositions, reshaping valuation methodologies across the industry [1] Group 1: Strategic Positioning - Baijia Pharmaceutical's strategic positioning focuses on avoiding "red ocean" competition in ADC and PD-1 fields, instead targeting traditional process upgrades and clinical application scenario transformations, which allows for shorter and more certain commercialization [2] - The founder's diverse background enables the company to accurately identify real clinical needs and hidden major products, avoiding common pitfalls in drug development [2] - Core products like KJ017 and SJ02 aim to enhance patient quality of life and medication convenience, effectively circumventing price pressures from national medical insurance [2] Group 2: Technological Barriers - The advanced biomanufacturing platform, represented by synthetic biology, is a core tool for Baijia Pharmaceutical's strategic differentiation [3] - The company has built a high-barrier biomanufacturing platform over six years, addressing challenges in large-scale expression, activity retention, and ultra-efficient purification of difficult recombinant enzymes [3] - The platform's zero animal-source production eliminates risks of viral contamination and severe allergic reactions, creating a "safety barrier" that cannot be undermined by price competition [3] Group 3: Industrialized Operations - Baijia Pharmaceutical integrates its technological advantages with industrialized operational capabilities to establish a "total cost leadership" structural moat [4] - Unlike many biotech companies relying on external CDMOs, Baijia Pharmaceutical has built and expanded large-scale cGMP production bases, becoming one of the few companies with commercial-scale production lines for mammalian, yeast, and E. coli fermentation [4] Group 4: Pipeline Structure - The synergy of strategic choice, technological barriers, and industrial advantages has led to Baijia Pharmaceutical's unique "pyramid-shaped" pipeline layout [6] - The base of the pipeline consists of products with short clinical cycles, low costs, and high market demand certainty, such as SJ02 and KJ017, which provide stable sales and cash flow [6] - The innovative projects at the top of the pyramid, like KJ103, are positioned as groundbreaking therapies with significant potential in treating autoimmune diseases, establishing the company as a high-value innovation engine [6] Group 5: Growth Model - Baijia Pharmaceutical's diversified and layered "two-legged" growth model enables it to achieve continuous, stable, and gradually increasing "slope-type" growth, avoiding the traditional "step-up" gambling model reliant on single product success [7] - This approach demonstrates the company's comprehensive competitiveness and long-term sustainability under the new valuation system [7] Summary - Baijia Pharmaceutical's rise is attributed to the organic synergy between its unique strategic positioning, technological pathways, production capabilities, and pipeline structure [8] - In a context where the biopharmaceutical industry faces "involution" challenges, the company offers a new innovation paradigm by focusing on clinical scenario innovation, technological upgrades, and strategic resilience [8]

Core Viewpoint - The Hong Kong stock market's 18A biotech sector is experiencing a resurgence in IPOs, with a significant shift in investor sentiment towards a more cautious evaluation of companies based on commercial maturity, cash flow sustainability, and clear value propositions [1] Group 1: Strategic Positioning - Baijia Pharmaceutical is strategically avoiding "red ocean" competition in areas like ADC and PD-1, focusing instead on upgrading traditional processes and transforming clinical application scenarios [2] - This strategy aims to optimize clinically validated drugs rather than pursuing high-risk new targets, effectively mitigating the high failure rates and long timelines associated with pure innovation drugs [2] - The founder, Dr. Liu Yanjun, leverages his diverse background to identify real clinical needs and hidden major products, avoiding common pitfalls in drug development [2] Group 2: Technological Barriers - Baijia Pharmaceutical has established a high-barrier advanced biomanufacturing platform, which is crucial for achieving strategic differentiation [3] - The platform addresses challenges in large-scale expression, activity retention, and ultra-efficient purification of complex recombinant enzymes [3] - The zero-animal-source production capability eliminates risks of viral contamination and severe allergic reactions, creating a "safety barrier" that cannot be undermined by price competition [3] Group 3: Industrial Operations - The company integrates its technological advantages with industrial operational capabilities to build a "total cost leadership" structural moat [4] - Unlike many biotech firms that rely on external CDMOs, Baijia Pharmaceutical has developed and expanded its own large-scale cGMP production facilities [4] - The company is among the few in China with commercial-scale production lines for mammalian engineering cells (CHO), yeast, and E. coli, achieving a "one-stop" full-platform system [4] Group 4: Pipeline Structure - The synergy of strategic choice, technological barriers, and industrial advantages has led Baijia Pharmaceutical to form a unique "pyramid-shaped" pipeline layout [6] - The base of the pipeline consists of products with short clinical cycles, low costs, and high market demand certainty, such as the approved SJ02 and the NDA-submitted KJ017, providing stable sales and cash flow [6] - The upper part of the pipeline focuses on high-barrier, disruptive potential innovation projects, exemplified by KJ103, which has received "breakthrough therapy designation" for its potential in treating autoimmune diseases [6] Group 5: Growth Model - Baijia Pharmaceutical's diversified and layered "two-legged" growth model enables it to achieve continuous, stable, and gradually increasing "slope-type" growth [7] - This approach successfully avoids the traditional "step-up" gambling model reliant on the success of a single product, showcasing comprehensive competitiveness and long-term sustainability under the new valuation system [7] Group 6: Conclusion - The rise of Baijia Pharmaceutical is not coincidental but a result of the organic synergy between its unique strategic positioning, technological route, production capabilities, and pipeline layout [8] - In the context of the widespread "involution" dilemma in the biopharmaceutical industry, Baijia Pharmaceutical offers a new innovation paradigm by focusing on clinical scenario innovation, technological upgrades, and strategic resilience [8]

Core Viewpoint - Baoyi Pharmaceutical-B (02659) has shown strong performance in the dark market, with a trading price of HKD 54, representing a 104.7% increase from the IPO price of HKD 26.38, indicating strong investor interest and confidence in the company's future prospects [1] Group 1: IPO Details - Baoyi Pharmaceutical plans to issue 37.91 million H-shares, with 90% allocated for international offerings and 10% for public offerings in Hong Kong [1] - The IPO price is set at HKD 26.38 per share, with an entry fee of approximately HKD 2,664.60 per hand [1] - The company has attracted significant cornerstone investors, with three well-known institutions participating and collectively subscribing HKD 200.6 million, accounting for 20.06% of the total fundraising [1] Group 2: Company Overview - Established in 2019 and headquartered in Shanghai, Baoyi Pharmaceutical is a biotechnology company focused on developing and providing recombinant biopharmaceuticals using advanced synthetic biology technology [2] - The company has a pipeline of 12 self-developed products, including three core products (KJ017, KJ103, and SJ02) and four other clinical candidates [2] Group 3: Product Pipeline and Market Potential - Baoyi Pharmaceutical's core products target four key therapeutic areas, including high-volume subcutaneous administration and antibody-mediated autoimmune diseases, with KJ017 being a recombinant hyaluronidase and KJ103 being a novel IgG-degrading enzyme [2][3] - The clinical addressable market for Baoyi Pharmaceutical's four strategic therapeutic areas in China is projected to reach approximately RMB 50 billion by 2033, driven by significant market sizes in each area [3] - The company has established a GMP-compliant production facility in Shanghai, covering approximately 63,000 square meters, equipped with specialized production lines for complex biopharmaceuticals [3] Group 4: Growth Potential - With its innovative product pipeline, strong R&D capabilities, and advanced production capacity, Baoyi Pharmaceutical demonstrates significant growth potential [4] - The company's entry into the capital market, supported by ample funding and a clear strategy, is expected to accelerate the commercialization of its core products and translate technological advantages into tangible performance growth [4]